The listing names sermorelin directly
The 2026 WADA Prohibited List includes sermorelin in the growth hormone-releasing hormone and analogs category under section S2. It also lists several related compounds, including CJC-1295, tesamorelin, and ipamorelin in their respective groupings.
For an athlete governed by these rules, a description such as peptide, secretagogue, or natural hormone support does not remove the ingredient from the list. The actual substance matters more than the marketing category.
Check the edition applying to your sport and competition period. This article’s review concerns the 2026 list; governing organizations and future editions should be consulted directly for an individual decision.
A prescription and sporting permission are different
A clinician can assess a medical problem, while the relevant anti-doping authority determines how sporting rules apply. Do not assume that having a prescription, receiving a pharmacy-labeled vial, or obtaining treatment through telehealth settles both questions.
If a medication is medically necessary, ask your sporting authority about its therapeutic use exemption process and requirements before treatment when possible. The application, supporting records, timing, and responsible authority need to be confirmed for your circumstances.
Your prescriber should know that you compete under anti-doping rules. That allows the medical discussion to include the actual condition, relevant alternatives, and any documentation the governing organization needs, rather than discovering the issue after a prescription has been filled.
WADA explains that athletes apply through the relevant anti-doping organization, rather than submitting an ordinary application directly to WADA. Its criteria include a supported medical diagnosis and consideration of permitted alternatives. Applying does not itself grant permission. Ask the organization to identify the process that applies to your level of competition and keep your clinician involved in preparing the required clinical information.
All-times restrictions need a year-round conversation
An all-times category is different from a restriction applying only during a competition period. Treating an off-season prescription as automatically outside the rules misunderstands that distinction.
Do not rely on a seller’s suggested clearance period, a forum estimate, or a claim that a short-acting peptide cannot matter by race day. This article does not provide detection windows or a strategy for timing use around testing.
The appropriate question is whether the treatment is permitted under the rules that govern you and, if necessary, whether the required exemption has been granted. Ask for a clear answer from the relevant authority rather than treating uncertainty as permission.
A prohibition is not a performance guarantee
Being listed does not establish how much, if at all, sermorelin would improve a particular athlete’s strength, endurance, or recovery. Anti-doping classification and evidence of clinical efficacy are different questions.
For example, a randomized trial in recreational athletes examined growth hormone rather than sermorelin and reported different findings across performance measures. Its results cannot be converted into an expected sermorelin advantage.
Our exercise-performance article explains those distinctions. A treatment can present a sporting eligibility issue even when its advertised benefits remain uncertain. Neither question should be used to obscure the other.
What to verify before a clinical appointment
Identify the anti-doping rules that apply to your federation, event, team, or testing program. Bring the full proposed ingredient list to the appropriate authority; a compounded blend may require review of more than one substance.
Ask your clinician to document the medical evaluation clearly, including whether there is a confirmed diagnosis or only an unexplained symptom. If you are already using a prescribed treatment, contact the clinician and sporting authority promptly for individualized advice rather than improvising a change.
Keep the correspondence and records relevant to the decision. The practical goal is coordinated medical care and a clear understanding of your obligations. A provider’s broad statement that a product is legal, natural, or available by prescription cannot replace a sport-specific answer.
Sources & further reading
Sources reviewed October 2026. Provider prices and terms may change.